Treace to Present at 42nd Annual J.P. Morgan Healthcare Conference
December 19 2023 - 7:00AM
Treace Medical Concepts, Inc. (“Treace” or the “Company”)
(NasdaqGS: TMCI), a medical technology company driving a
fundamental shift in the surgical treatment of bunions and related
midfoot deformities through its flagship Lapiplasty® and
Adductoplasty® Procedures, today announced that John T. Treace,
Chief Executive Officer, will present at the 42nd Annual J.P.
Morgan Healthcare Conference on Tuesday, January 9, 2024, beginning
at approximately 3:45 pm Pacific Time.
A live webcast and replay of the fireside chat
will be available on the Company’s investor relations website at
https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be
important to investors in the “Investor Relations” section of its
website at www.treace.com. The company encourages investors and
potential investors to consult the Treace website regularly for
important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical
technology company with the goal of advancing the standard of care
for the surgical management of bunion and related midfoot
deformities. Bunions are complex 3-dimensional deformities that
originate from an unstable joint in the middle of the foot and
affect approximately 65 million Americans, of which Treace
estimates 1.1 million are annual surgical candidates. Treace has
pioneered and patented the Lapiplasty® 3D Bunion Correction® System
– a combination of instruments, implants, and surgical methods
designed to surgically correct all 3 planes of the bunion deformity
and address the root cause of the bunion, helping patients get back
to their active lifestyles. Treace expanded its offering with the
Adductoplasty® Midfoot Correction System, designed for reproducible
correction of midfoot deformities, as well as its PEEK Hammertoe
arthrodesis system, to further support the needs of bunion
patients. The company continues to expand its footprint in the foot
and ankle market with the introduction of its SpeedPlate™ Rapid
Compression Implants, an innovative fixation platform with broad
versatility across Lapiplasty® and Adductoplasty® procedures, as
well as other common bone fusion procedures of the foot. For more
information, please visit www.treace.com.
To learn more about Treace, connect with us on
LinkedIn, Twitter, Facebook and Instagram.
Contacts:
Treace Medical ConceptsJulie Dewey, IRCChief
Communications & Investor Relations Officerjddewey@treace.com |
209-613-6945
Treace Medical Concepts (NASDAQ:TMCI)
Historical Stock Chart
From Apr 2024 to May 2024
Treace Medical Concepts (NASDAQ:TMCI)
Historical Stock Chart
From May 2023 to May 2024